ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors
Exclusive license from Helmholtz Munich will enable ITM to access IP and know-how to develop…
Month: October 2022
Aquestive Therapeutics to Report Third Quarter 2022 Financial Results and Recent Business Highlights on November 1 and Host Conference Call on November 2 at 8:00 a.m. ET
WARREN, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical…
Providence Announces Positive Top-Line Data from Phase 2 Primary Immunization Trial of its mRNA Vaccine Candidate PTX-COVID19-B in Adults
PTX-COVID19-B was well tolerated with no safety signals Non-inferior neutralizing antibody titer levels versus comparator…
Umoja Biopharma to Present Three Posters Data on its Integrated In Vivo CAR T and ShRED Platform Technologies at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
SEATTLE, Oct. 19, 2022 (GLOBE NEWSWIRE) — Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf,…
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara’s Software for Evaluating Regulatory Submissions
The PMDA enters 9th consecutive year of using Certara’s software PRINCETON, N.J., Oct. 19, 2022…
INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune
Dr. Mark Lowdell, CSO, Presented Latest Data in First Plenary Session at The Innate Killer…
Galecto’s Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute
Phase 2 investigator-initiated trial to be supported by an NCI grant to Providence Cancer Institute…
Hepion Pharmaceuticals to Participate in the ThinkEquity Conference
EDISON, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage…
AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022
Enrollment Ongoing in Phase 2/3 Pivotal Trial of Epetraborole in Treatment- Refractory MAC Lung Disease…
PDS Biotech to Present at the LD Micro Main Event XV
FLORHAM PARK, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a…
Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting
WILMETTE, Ill., Oct. 19, 2022 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical…
Cocrystal Pharma to Present at the LD Micro Main Event XV
BOTHELL, Wash., Oct. 19, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that…
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022
— Presentations Reinforce Topline Safety and Efficacy Findings and Highlight Consistency between Clinical and Microbiological…
Nephros Third Quarter 2022 Financial Results Conference Call
SOUTH ORANGE, NJ, Oct. 19, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Nephros, Inc. (Nasdaq:…
Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022
Highlighting Ocugen research and innovative technologies Featuring thought leaders in gene therapy and vaccines MALVERN,…
Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
NEW YORK and CLEVELAND, Oct. 19, 2022 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO)…
Sinaptica Therapeutics Announces FDA Breakthrough Device Designation for its Novel Noninvasive Neurostimulation Treatment for Alzheimer’s Disease
SinaptiStim™ – AD System provides personalized and precision-delivered electromagnetic therapeutic approach to treating cognitive and…
Matinas BioPharma Announces Infectious Diseases Society of America (IDSA) has Selected the EnACT Phase 2 Trial Abstract of MAT2203 as its Outstanding Abstract and IDSA Awardee For IDWeek 2022
BEDMINSTER, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB),…
Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
BOSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company…
Tonix Pharmaceuticals to Present at the 2022 ThinkEquity Conference
CHATHAM, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a…